Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma

12 Apr 2017

Abstract excerpt

To positively modulate multiple myeloma (MM) bone disease, understanding the mechanism of bone destruction is required to provide better targeted therapy. Specific molecular genetic lesions and tumor cell–stroma interactions influence the clinical course and response to therapy, all of which can vary markedly. 1 , 2 Our recent study demonstrates that an increased chromosomal instability (CIN) signature is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone health and treatments
Share to Multiple Myeloma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28400617
DOI: 10.1038/leu.2017.115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myelomaPMID 28400617Read ↗

Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells.Semantic proximity Read ↗

Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple MyelomaSemantic proximity Read ↗

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.Semantic proximity Read ↗

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myelomaSemantic proximity Read ↗

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaSemantic proximity Read ↗

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].Semantic proximity Read ↗

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myelomaSemantic proximity Read ↗

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destructionSemantic proximity Read ↗

Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatinsSemantic proximity Read ↗

Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival.Semantic proximity Read ↗

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast DifferentiationSemantic proximity Read ↗

Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.